Checkpoint inhibitors in bladder and renal cancers: results and perspectives

被引：20

作者：

Aoun, Fouad ^{[1
]}

Kourie, Hampig R. ^{[2
]}

Sideris, Spyridon ^{[2
]}

Roumeguere, Thierry ^{[3
]}

van Velthoven, Roland ^{[1
]}

Gil, Thierry

机构：

[1] Inst Jules Bordet, Dept Urol, B-1000 Brussels, Belgium

[2] Inst Jules Bordet, Dept Oncol, B-1000 Brussels, Belgium

[3] Erasme Univ Hosp, Dept Urol, B-1070 Brussels, Belgium

来源：

IMMUNOTHERAPY | 2015年 / 7卷 / 12期

关键词：

bladder cancer; checkpoint inhibitors; CTLA4; immunotherapy; PD1/PDL1; renal cell carcinoma; TRANSITIONAL CELL-CARCINOMA; CLINICAL ACTIVITY; INTERFERON-ALPHA; TUMOR-CELL; HLA-G; BLOCKADE; IMMUNOTHERAPY; SURVIVAL; ANTIBODY; NIVOLUMAB;

D O I：

10.2217/imt.15.91

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The field of immunotherapy in urinary malignancy is expanding in several directions and checkpoint inhibitors are leading the way. The aim of this report is to highlight the efficacy and safety profile of the two classes of molecules, anti-cytotoxic T-lymphocyte antigen-4 and anti-programmed death receptor-1/programmed death ligand type 1, that are under investigation and represent potential candidates to be used in the near future for the management of bladder and renal cell cancer. The preliminary results as well as the future perspectives of this novel immunotherapy are analyzed. Novel immune checkpoint targets are reviewed as well.

引用

页码：1259 / 1271

页数：13

共 65 条

[1]

Amin A, 2014, ANN ONCOL S24, V25, p[580, iv362]

[2] METASTASES FROM TRANSITIONAL CELL-CARCINOMA OF URINARY-BLADDER [J].

BABAIAN, RJ ;

JOHNSON, DE ;

LLAMAS, L ;

AYALA, AG .

UROLOGY, 1980, 16 (02) :142-144

[3] Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4 [J].

Beck, Kimberly E. ;

Blansfield, Joseph A. ;

Tran, Khoi Q. ;

Feldman, Andrew L. ;

Hughes, Marybeth S. ;

Royal, Richard E. ;

Kammula, Udai S. ;

Topalian, Suzanne L. ;

Sherry, Richard M. ;

Kleiner, David ;

Quezado, Martha ;

Lowy, Israel ;

Yellin, Michael ;

Rosenberg, Steven A. ;

Yang, James C. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (15) :2283-2289

[4] The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation [J].

Blank, Christian U. .

CURRENT OPINION IN ONCOLOGY, 2014, 26 (02) :204-214

[5] Cytotoxic T-Lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer [J].

Blansfield, JA ;

Beck, KE ;

Tran, K ;

Yang, DC ;

Hughes, MS ;

Kammula, US ;

Royal, RE ;

Topalian, SL ;

Haworth, LR ;

Levy, C ;

Rosenberg, SA ;

Sherry, RM .

JOURNAL OF IMMUNOTHERAPY, 2005, 28 (06) :593-598

[6] Immunotherapy of cancer [J].

Borghaei, Hossein ;

Smith, Mitchell R. ;

Campbell, Kerry S. .

EUROPEAN JOURNAL OF PHARMACOLOGY, 2009, 625 (1-3) :41-54

[7] Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer [J].

Brahmer, Julie R. ;

Tykodi, Scott S. ;

Chow, Laura Q. M. ;

Hwu, Wen-Jen ;

Topalian, Suzanne L. ;

Hwu, Patrick ;

Drake, Charles G. ;

Camacho, Luis H. ;

Kauh, John ;

Odunsi, Kunle ;

Pitot, Henry C. ;

Hamid, Omid ;

Bhatia, Shailender ;

Martins, Renato ;

Eaton, Keith ;

Chen, Shuming ;

Salay, Theresa M. ;

Alaparthy, Suresh ;

Grosso, Joseph F. ;

Korman, Alan J. ;

Parker, Susan M. ;

Agrawal, Shruti ;

Goldberg, Stacie M. ;

Pardoll, Drew M. ;

Gupta, Ashok ;

Wigginton, Jon M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2455-2465

[8] Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates [J].

Brahmer, Julie R. ;

Drake, Charles G. ;

Wollner, Ira ;

Powderly, John D. ;

Picus, Joel ;

Sharfman, William H. ;

Stankevich, Elizabeth ;

Pons, Alice ;

Salay, Theresa M. ;

McMiller, Tracee L. ;

Gilson, Marta M. ;

Wang, Changyu ;

Selby, Mark ;

Taube, Janis M. ;

Anders, Robert ;

Chen, Lieping ;

Korman, Alan J. ;

Pardoll, Drew M. ;

Lowy, Israel ;

Topalian, Suzanne L. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) :3167-3175

[9] A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma [J].

Brignone, Chrystelle ;

Escudier, Bernard ;

Grygar, Caroline ;

Marcu, Manon ;

Triebel, Frederic .

CLINICAL CANCER RESEARCH, 2009, 15 (19) :6225-6231

[10] Immunoexpression of B7-H3 in endometrial cancer: Relation to tumor T-cell infiltration and prognosis [J].

Brunner, Andreas ;

Hinterholzer, Susanne ;

Riss, Paul ;

Heinze, Georg ;

Brustmann, Hermann .

GYNECOLOGIC ONCOLOGY, 2012, 124 (01) :105-111

← 1 2 3 4 5 6 7 →